SMMT Summit Therapeutics PLC
Company Analysis
Latest News
🟢 Summit Therapeutics is trading 4.71% up in pre-market after major U.S. indexes rose overnight
Summit Therapeutics is trading at $18.69, up +4.71%, after a firm overnight market backdrop lifted major U.S. indexes. • The S&P 500 rose 0.69% and Nasdaq...
🟢 Summit Therapeutics rises 4.2% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Summit Therapeutics falls 4.0% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Summit Therapeutics Reports Favorable Ivonescimab Survival Data from Phase III HARMONi Trial
Summit Therapeutics announced updated, positive overall survival (OS) results from its global Phase III HARMONi clinical trial for ivonescimab in patients with...
Summit's Lung-Cancer Drug Just Beat the World's Best-Selling Cancer Treatment — But Can a $13 Billion Company With Zero Revenue Cash That Check?
Shares shifted as Summit Therapeutics surged 6.1% to $18.59 on a down day for the broader market, powered by data showing its partner Akeso's experimental...
🟢 Summit Therapeutics is trading 6.1% up today after Akeso reported positive ivonescimab survival data
Summit Therapeutics is trading 6.1% up now at $18.59 after partner Akeso reported updated HARMONi-2 results showing ivonescimab extended median overall...
Summit's Ivonescimab Shows 8.2-Month Survival Benefit Over Pembrolizumab in NSCLC Trial
Summit Therapeutics announced that its partner, Akeso Inc., reported positive updated overall survival (OS) data from the Phase III HARMONi-2 trial. The study...
🟢 Summit Therapeutics is trading 5.7% up in pre-market after partner Akeso reported significant ivonescimab overall-survival results
Summit Therapeutics is trading at $18.55 (+5.70%) after partner Akeso reported statistically significant, clinically meaningful overall-survival results for...
🟢 Summit Therapeutics is trading 4.12% up today as U.S. equities advance
Summit Therapeutics is trading 4.12% higher at $17.70 as U.S. equities advance following August inflation data and improving risk appetite. - Major indexes...
🔴 Summit Therapeutics is trading 4.05% down today after hotter-than-expected producer inflation
Summit Therapeutics is trading at $16.83, with a -4.05% change, as U.S. markets sell off after hotter-than-expected producer inflation and elevated oil...
Summit Therapeutics Surges on Jefferies Upgrade, Citing Potential Cancer Drug Breakthrough
Jefferies upgraded Summit Therapeutics (SMMT) to Buy from Hold. Analysts raised the price target for the biopharmaceutical company from $15 to $25. Shares rose...
🟢 Summit Therapeutics is trading 4.05% up in pre-market after positive HARMONi-2 survival results
Summit Therapeutics is trading 4.05% up in pre-market at $17.98, driven by continued investor interest in positive HARMONi-2 Phase 3 results from partner...
Summit's Cancer Drug Showed It Can Help Patients Live Longer — But Can a Zero-Revenue Biotech Justify a $12 Billion Bet?
Shares of Summit Therapeutics surged 7.5% to $15.70 after partner Akeso announced that its experimental cancer drug beat Merck's blockbuster Keytruda — the...
Ivonescimab Shows Superior Overall Survival vs. Pembrolizumab in Phase III Lung Cancer Study
Summit Therapeutics announced that its partner, Akeso Inc., reported positive overall survival (OS) results from the Phase III HARMONi-2 study. The trial...
🟢 Summit Therapeutics is trading 10.3% up today after Akeso announced statistically significant overall-survival improvement
Summit Therapeutics is trading 10.3% up now at $16.10 after partner Akeso announced statistically significant overall-survival improvement for ivonescimab...
🟢 Summit Therapeutics is trading 7.53% up today after Akeso reports significant overall-survival benefits
Summit Therapeutics is trading 7.53% up today at $15.70 after partner Akeso reported statistically significant, clinically meaningful overall-survival benefits...
🟢 Summit Therapeutics is trading 4.62% up in pre-market after Akeso reported statistically significant HARMONi-2 survival benefits
Summit Therapeutics is trading 4.62% up now at $15.27 after partner Akeso reported statistically significant overall-survival benefits for ivonescimab versus...
🟢 Summit Therapeutics is trading 4.3% up today; catalyst remains unclear
Summit Therapeutics is trading at $14.20, up 4.26%, with no new September 1, 2026 company-specific announcement or direct catalyst identified. - Recent...
🔴 Summit Therapeutics falls 4.3% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Summit Therapeutics is trading 5.76% up in pre-market after partner Akeso reported HARMONi-GI1 survival superiority
Summit Therapeutics is trading at $15.05 (+5.76%) after partner Akeso reported statistically significant overall-survival superiority in the Phase III...